Specialty Life Sciences Company

Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (CSE: RVV) is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. The Company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantation. With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.

FDA Approved Phase 3 Study ​Bucillamine for the Treatment of COVID-19

Revive Therapeutics Ltd. (CSE: RVV) (OTCQP: RVVTF) is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocal to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-10…more.

Acquistion of Psilocin Pharma Corp.

Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Their intellectual property cover methods of production of Psilocybin based formulations.  Visit psilocinpharma.com

Click here for press release regarding the acquisition.

Investor Deck – October 2020

Latest Press Releases